Ruth Devenyns, CEO of Precirix, commented: “We are very pleased to welcome Niva to the team, marking our first US hire and highlighting Precirix’s global ambition. Niva’s long-standing experience in biotech partnering and her knowledge of the radiopharmaceuticals space will be truly valuable in leveraging our innovative technology platform.”
Prior to joining Precirix, Dr. Almaula led business development at Advanced Accelerator Applications Inc., building the diagnostic and therapeutic radiopharmaceuticals pipeline preceding its USD 3.9bn acquisition by Novartis. Additionally, she has worked in different roles at the nexus of science and business, in search and evaluation at Nycomed, (now Takeda), alliance management for biosimilars at Dr Reddy’s Labs and in academic technology transfer at Rockefeller University. She started her career in biotechnology equity research, has a PhD in biochemistry and molecular biology from Rutgers University and conducted postdoctoral research in molecular neurobiology at Mount Sinai Medical Center.
On her appointment, Dr. Niva Almaula stated: “Very happy to be joining Precirix at an optimal time to engage in external out-reach and partnership discussions for the company’s technology platform and programs. With CAM-H2 in clinical development, two additional drug candidates in preclinical development from its single domain antibody platform for targeted delivery of radionuclides, and overall capabilities in radiopharmaceutical development, Precirix is a leader in the development of next generation radiotherapeutics.”
Precirix is a private, clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing precision radiopharmaceuticals, using camelid single-domain antibodies (sdAb) labeled with radioisotopes. The company has a broad pipeline with one product candidate in a Phase I/II clinical trial and two in advanced preclinical stage. Research on multiple isotopes, linker technology and combination therapies further expand the platform. Precirix’ technology also allows for a theranostic approach, where patients can be selected using a low dose/imaging version of the product, followed by a higher therapeutic dose.
Your browser is not supported. Update your browser for more security, speed and to make the most of this site.